Camrelizumab plus gemcitabine and oxaliplatin for relapsed or refractory classical Hodgkin lymphoma: a phase II trial

Results of a study investigating camrelizumab combined with gemcitabine and oxaliplatin for treatment of relapsed Hodgkin lymphoma.